iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
138 hedge funds and large institutions have $383M invested in iTeos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 36 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $389M → $383M (-$5.18M)
1.35% less ownership
Funds ownership: 99.18% → 97.83% (-1.3%)
4% less funds holding
Funds holding: 144 → 138 (-6)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
86% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.1M |
| 2 |
Morgan Stanley
New York
|
+$8.62M |
| 3 |
Renaissance Technologies
New York
|
+$3.02M |
| 4 |
Citigroup
New York
|
+$2.56M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.2M |
| 2 |
BlackRock
New York
|
-$7.82M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.6M |
| 4 |
Janus Henderson Group
London,
|
-$5.48M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.2M |
ITOS Hedge Fund Activity: Q4 2023 in Review
138 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2023, worth a combined $383M — down 1.3% from $389M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ITOS and 32 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 48 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $11.1M. The largest seller was State Street, cutting an estimated $10.2M.
- 138 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2023, down from 144 in Q3 2023.
- Funds reported $383M of iTeos Therapeutics stock for Q4 2023, down 1.3% quarter-over-quarter.
- 32 funds opened new iTeos Therapeutics positions in Q4 2023 and 36 closed out, a net change of -4 holders.
- The largest iTeos Therapeutics buyer in Q4 2023 was EcoR1 Capital, an estimated $11.1M added.
- The largest iTeos Therapeutics seller in Q4 2023 was State Street, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2023.